Body mass index and response to infliximab in rheumatoid arthritis.

@article{Ottaviani2015BodyMI,
  title={Body mass index and response to infliximab in rheumatoid arthritis.},
  author={S{\'e}bastien Ottaviani and Anais Gardette and Florence Tubach and Carine Roy and Elisabeth Palazzo and Ghislaine Gill and Olivier Meyer and Philippe Dieud{\'e}},
  journal={Clinical and experimental rheumatology},
  year={2015},
  volume={33 4},
  pages={478-83}
}
OBJECTIVES Excess adipose tissue in obese individuals may have immunomodulating properties and pharmacokinetics consequences. Previous studies have suggested that obesity could negatively affect the response to anti-TNF-α agents, notably infliximab (IFX). We aimed to determine whether body mass index (BMI) is involved in the response to IFX in rheumatoid arthritis (RA). METHODS We retrospectively examined data for 76 RA patients receiving IFX. BMI was calculated before treatment, and change… CONTINUE READING